Alliance Pharma

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

Alliance Pharma report continued strong trading, with revenue up more than 40%

Tuesday, July 06, 2010 by Jamie Ashcroft

In an update ahead of its first half results, Alliance Pharma (LON:APH) told investors it continues to benefit from strong trading with year-on-year revenues up 40%, excluding revenues from recently acquired products. Overall, in the six-months ended 30 June 2010, the company generated revenues of approximately £23.4m, up more than £10m from the first half of 2009.

Alliance highlighted that the sales from Deltacortril/enteric coated prednisolone continued to be strong during the period.

The new product portfolio, acquired from Cambridge Laboratories in 2010, is performing in line with the company’s expectations. The Cambridge Laboratories deal added 18 new prescription products to Alliance’s portfolio, and it is expected to be significantly earnings enhancing in the current financial year. The portfolio of 18 prescription products covers a broad range of therapeutic areas including oncology, toxicology and others.

Proactiveinvestors recommends

The interim results for the six months period are scheduled for release on 8 September 2010.

This latest guidance on the company’s trading performance reflects Alliance Pharma’s continued momentum from a strong FY09 financial year. In late March, Alliance published its results from 2009, in which the pharmaceutical company increased sales by 44% to £31.2 million compared with 21.8 million in the previous financial year. The company achieved a three-fold increase in pre-tax profit before exceptionals to £8.6 million as well as in adjusted earnings per share (EPS) to 3.55 pence.

According to Alliance its record sales performance in 2009, reflected the company’s transition to the new business model, set out in 2007, with the benefits clearly evidenced in the results. Alliance said that the development side of the business is now in abeyance, with no investment of any substance made last year, no further plans to do so.

Through its concentration on the trading side of its business, the company said it has reached a critical mass of human, product and financial resources which enable it to invest confidently in adding more established products to its portfolio.

Wiltshire-based Alliance Pharma was founded in 1998, and since then it has established a strong track record of acquiring the rights to established niche products. The company now owns/or licences over 50 prescription products, across a broad range of therapeutic areas – including ‘Anti Infective’, Cardiovascular, Obstetrics & Gynaecology, Toxicology, Oncology, Rheumatology and many others.

Yesterday, the company reported that its second largest shareholder, Nigel Wray bought 1.9 million shares, to increase his holding to 27.9 million shares, taking his stake in the company to approximately 12.03%. Wray remains the company’s second largest shareholder behind Chief Executive John Dawson - who controls 46.6 million shares, or 20.17%.

Wray has been topping up his shareholding in the company over recent months, buying 0.75 million shares in May (for 11.08%) and buying a further 0.8 million in June (for 11.26%).

Investors interested in Alliance Pharma recently viewed

Company Articles
Company News
Sector News
Alliance Pharma Archive

Alliance Pharma trading ahead of expectations

The Cambridge Laboratories acquisition has been successfully integrated ahead of schedule, and the group looks forward to the rest of 2010 with confidence.
Alliance Pharma reports landmark full-year results with strong growth

Sales rose 44 percent from a year earlier, driven by its rheumatology product Deltacortril, and the group is confident of further strong results in 2010.
Alliance Pharma gains 18 new prescription products in acquisition

The company is paying up to £17.8m for privately owned Cambridge Laboratories and expects the deal to be significantly earnings enhancing in the current full year.
Alliance Pharma: standing the test of time

The focus on prescription drugs means a stable revenue stream, while the fact that Alliance has a portfolio of 35 of these brands means that it is not overly dependent upon any one product for its overall revenues.
Alliance Pharma to buy 2 Reckitt Benckiser drugs for £7.5 mln

Alliance Pharma PLC (AIM: APH) said it is buying the worldwide rights to the Buccastem and Timodine brands from various subsidiaries of Reckitt Benckiser Group PLC (LSE: RB) for £7.5 million, of which it will pay £3.7 million ia a vendor share placing.

Cyprotex Duo Map Out Ambitous Growth Plans

A chat with Tony Baxter and John Dootson reveals Cyprotex is in rude health - and has some ambitous plans to grow.
City Analysts Upbeat After Biocompatibles’ Strong Interims

Both Nomura Code and Piper Jaffray upbreat after the growing bio-tech firm posted forecast-beating interim results.
Asterand 'has weathered the worst of the storm'

Chief Excutive Martyn Coombs believes the company has weathered the worst of the storm in the contract research market, and analyst forecasts see Asterand making up lost ground in the second half.
Plant Impact Chief Exec Peter Blezard says Syngenta collaboration is potentially ‘huge’

The company is tying up with the Brazilian arm of the Swiss agri-giant to carry out a field study on its ecologically friendly crop nutrition and protection products.
ReNeuron's Hunt on the Challenges Facing the Stem Cell Pioneer

ReNeuron's Micheal Hunt talks us through a landmark period for the company and the challenges that lie ahead.
Golden Silence Prospers as Investors Digest Novartis Deal

Shares in Silence Therapeutics rose 20 per cent as the market continued to digest the news the group could earn as much as $65 million from a collaboration deal with Swiss giant Novartis.
A bumpy ride, but Silence has options

It's been tough since its merger with US-based Intradigm at the start of the year. Investor concerns centre on a potential funding shortfall, but there are reasons to believe boss Philip Haworth and his team will find new sources of finance before the deadline date.
Biocompatibles reports good start to financial year

After reporting very good progress for the 2009 full-year in March, the company now announced that revenues in the current year to date are already ahead of board expactations.
Plant Impact reports positive field trial results for potatoes

Initial trial results for the company's PiNT yield optimiser and CaT calcium absorption technologies shows potato volumes up by more than 25 percent and significant increases in yield.
Asterand: investing for the future

The group is looking ahead with optimism as human tissue testing is becoming mission critical to the pharmaceutical industry. Asterand is well placed in a market that is growing.

Stocktube video

16/07/2010

Alliance Pharma confirm they are on track with promising growth prospects

View full size

Additional Information

Market:	AIM
Sector:	Pharmaceuticals & Biotechnology
EPIC:	APH
Latest Price:	36.75p (-1.34% )
52-week High:	37.75p
52-week Low:	16.75p
Market Cap:	86.62M

1 year chart

1 day chart

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.